Evidence map›Paper›PMID 41988105›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2026

Long-Term Evaluation of Autologous Serum Eye Drops in Dry Eye Disease.

Mélanie Velier, Justine Champoussin, Loic Dambricourt, Cecilia Bec, Albert Darque, Celia Lento, Julie Veran, Chloé Dumoulin, Francoise Dignat-George, Thierry David and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mélanie VelierCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.ORCID 0000-0002-1121-8270
Justine ChampoussinCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.
Loic DambricourtOphtalmology Department, CHU Conception, AP-HM, Marseille, France.
Cecilia BecCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.
Albert DarquePharmacy Department, CHU Conception, AP-HM, Marseille, France.
Celia LentoPharmacy Department, CHU Conception, AP-HM, Marseille, France.
Julie VeranCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.
Chloé DumoulinCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.
Francoise Dignat-GeorgeAix-Marseille Univ, C2VN, INSERM 1263, INRAE1260, Marseille, France.
Thierry DavidOphtalmology Department, CHU Conception, AP-HM, Marseille, France.
Florence SabatierCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.
Jeremy MagalonCulture and Cell Therapy Laboratory, INSERM CIC BT 1409, CHU Conception, AP-HM, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry eye disease (DED) remains a therapeutic challenge, particularly in refractory cases. While autologous serum eye drops (ASED) offer short-term benefits, data on their long-term efficacy are scarce. This retrospective longitudinal study evaluated patients treated with ASED for at least three years, with follow-ups at three time points (T1, T2 and T3). Our findings demonstrate that most patients (65.5% at T1, 60% at T2, 65.5% at T3), exhibit a robust and sustained response to ASED therapy over the years, suggesting the potential to identify a responder profile based on early treatment outcomes. Larger-scale studies are needed to clarify the factors underlying this profile, which could ultimately guide personalized therapeutic strategies for DED.

Indexed as

autologous serum eye dropdry eye diseaselong-term outcomesocular surface disease

Identifiers

PMID41988105
PMCPMC13077459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.